Studies have shown that in primary glioma models (U251 and SHG-44), XHP treatment alone downregulated POU4F1 and STAT3 levels and increased LDH release and IL-1β and IL-18 levels, and the apoptosis-associated factor NLRP3 was activated. Here, NLRP3 is linked to central nervous system cancer.